Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-22-008159
Filing Date
2022-02-09
Accepted
2022-02-09 17:52:55
Documents
1
Period of Report
2022-02-08

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 5844
  Complete submission text file 0001209191-22-008159.txt   7281
Mailing Address C/O TETRAPHASE PHARMACEUTICALS, INC. 480 ARSENAL STREET, SUITE 110 WATERTOWN MA 02472
Business Address
Lubner David Charles (Reporting) CIK: 0001572000 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-41259 | Film No.: 22608577

Mailing Address 25 WEST WATKINS MILL ROAD SUITE A GAITHERSBURG MD 20878
Business Address 25 WEST WATKINS MILL ROAD SUITE A GAITHERSBURG MD 20878 240-723-6641
Arcellx, Inc. (Issuer) CIK: 0001786205 (see all company filings)

EIN.: 472855917 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)